190 related articles for article (PubMed ID: 30362139)
1. Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan.
Liu CH; Yu ML; Peng CY; Hsieh TY; Huang YH; Su WW; Cheng PN; Lin CL; Lo CC; Chen CY; Chen JJ; Ma Q; Brooks-Rooney C; Kao JH
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1290-1300. PubMed ID: 30362139
[TBL] [Abstract][Full Text] [Related]
2. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
Kawaguchi I; Chayama K; Gonzalez YS; Virabhak S; Mitchell D; Yuen C; Kumada H
Adv Ther; 2020 Jan; 37(1):457-476. PubMed ID: 31808054
[TBL] [Abstract][Full Text] [Related]
3. Drug-Drug Interactions in Children and Adolescents Receiving Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Virus Infection.
Abdullatif HM; Ramzi R; Mogahed EA; Ghobrial CM; El Rasheed Abd El Zaher BA; El Raziky MS; El-Karaksy HM
Clin Drug Investig; 2019 Sep; 39(9):857-864. PubMed ID: 31240576
[TBL] [Abstract][Full Text] [Related]
4. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis.
Hsu PY; Wei YJ; Lee JJ; Niu SW; Huang JC; Hsu CT; Jang TY; Yeh ML; Huang CI; Liang PC; Lin YH; Hsieh MY; Hsieh MH; Chen SC; Dai CY; Lin ZY; Chen SC; Huang JF; Chang JM; Hwang SJ; Chuang WL; Huang CF; Chiu YW; Yu ML
Clin Mol Hepatol; 2021 Jan; 27(1):186-196. PubMed ID: 33317251
[TBL] [Abstract][Full Text] [Related]
5. The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection.
Garrison KL; German P; Mogalian E; Mathias A
Drug Metab Dispos; 2018 Aug; 46(8):1212-1225. PubMed ID: 29695614
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.
Kawakami Y; Ochi H; Hayes CN; Imamura M; Tsuge M; Nakahara T; Katamura Y; Kohno H; Kohno H; Tsuji K; Takaki S; Mori N; Honda Y; Arataki K; Takahashi S; Kira S; Tamura T; Masuda K; Nakamura T; Kikkawa M; Chayama K
J Gastroenterol; 2018 Apr; 53(4):548-556. PubMed ID: 28815329
[TBL] [Abstract][Full Text] [Related]
7. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs.
Roncero C; Villegas JL; Martínez-Rebollar M; Buti M
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):999-1030. PubMed ID: 30199279
[TBL] [Abstract][Full Text] [Related]
8. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
[TBL] [Abstract][Full Text] [Related]
9. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ
J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754
[TBL] [Abstract][Full Text] [Related]
10. Utilizing Clinical Pharmacist Specialist to Manage Hepatitis C Virus Patients on Direct-Acting Antiviral Therapy.
Mikolas LA; Jacques K; Huq M; Krasner C; Mambourg SE
J Pharm Pract; 2019 Dec; 32(6):655-663. PubMed ID: 29783912
[TBL] [Abstract][Full Text] [Related]
11. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
Shiha G; Esmat G; Hassany M; Soliman R; Elbasiony M; Fouad R; Elsharkawy A; Hammad R; Abdel-Razek W; Zakareya T; Kersey K; Massetto B; Osinusi A; Lu S; Brainard DM; McHutchison JG; Waked I; Doss W
Gut; 2019 Apr; 68(4):721-728. PubMed ID: 29666174
[TBL] [Abstract][Full Text] [Related]
12. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program.
Gray E; O'Leary A; Bergin C; Cannon M; Courtney G; Crosbie O; De Gascun CF; Fanning LJ; Feeney E; Houlihan DD; Kelleher B; Lambert JS; Lee J; Mallon P; McConkey S; McCormick A; McKiernan S; McNally C; Murray F; Sheehan G; Stewart S; Walsh C; Norris S;
Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):593-601. PubMed ID: 28276815
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
Liu CJ; Chuang WL; Sheen IS; Wang HY; Chen CY; Tseng KC; Chang TT; Massetto B; Yang JC; Yun C; Knox SJ; Osinusi A; Camus G; Jiang D; Brainard DM; McHutchison JG; Hu TH; Hsu YC; Lo GH; Chu CJ; Chen JJ; Peng CY; Chien RN; Chen PJ
Gastroenterology; 2018 Mar; 154(4):989-997. PubMed ID: 29174546
[TBL] [Abstract][Full Text] [Related]
15. Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment-experienced individual.
Johnson SW; Davis MM; Stever LM; Priest DH
J Clin Pharm Ther; 2016 Dec; 41(6):727-729. PubMed ID: 27670742
[TBL] [Abstract][Full Text] [Related]
16. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.
Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Feb; 89(2):284-290. PubMed ID: 27357737
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan.
Ward T; Webster S; Mishina S; McEwan P; Wygant G; Wang F
Value Health Reg Issues; 2017 May; 12():1-6. PubMed ID: 28648305
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain.
Sicras Mainar A; Navarro Artieda R; Hernández I; Morillo R
Gastroenterol Hepatol; 2019 Oct; 42(8):465-475. PubMed ID: 31451229
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen.
Bourgeois S; Horsmans Y; Nevens F; van Vlierberghe H; Moreno C; Beumont M; Vijgen L; van Eygen V; Luo D; Hillewaert V; Van Remoortere P; van de Logt J; Ouwerkerk-Mahadevan S
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971875
[TBL] [Abstract][Full Text] [Related]
20. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice.
Macías J; Monge P; Mancebo M; Merchante N; Neukam K; Real LM; Pineda JA
HIV Med; 2017 Aug; 18(7):445-451. PubMed ID: 27882706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
